Effects of morphine, physostigmine and raphe nuclei stimulation on 5-hydroxytryptamine release from the cerebral cortex of the cat

P Aiello-Malmberg, A Bartolini, R Bartolini, A Galli, P Aiello-Malmberg, A Bartolini, R Bartolini, A Galli

Abstract

1. The release of 5-hydroxytryptamine (5-HT) from the cerebral cortex and caudate nucleus of brainstem-transected cats and from the cerebral cortex of rats anaesthetized with urethane was determined by radioenzymatic and biological assay. 2. The stimulation of nucleus linearis intermedius of raphe doubles the basal 5-HT release in the caudate nucleus and increases it 3 fold in the cerebral cortex. The effects of the electrical stimulation of the raphe are potentiated by chlorimipramine. 3. Brain 5-HT release is greatly increased by morphine hydrochloride (6 mg/kg i.v.) and by physostigmine (100 microgram/kg i.v.), but not by DL-DOPA (50 mg/kg i.v.). 4. It is suggested that the 5-HT releasing action of physostigmine can contribute to some of its pharmacological effects such as the analgesic effect so far attributed exclusively to its indirect cholinomimetic activity. 5. The 5-HT releasing action of physostigmine seems unrelated to its anticholinesterase activity.

References

    1. J Physiol. 1963 Jan;165(1):98-116
    1. J Physiol. 1961 Jan;155:1-27
    1. J Neurochem. 1961 Feb;6:226-32
    1. Proc Soc Exp Biol Med. 1958 Jan;97(1):97-100
    1. Br J Pharmacol Chemother. 1957 Sep;12(3):344-9
    1. Jpn J Pharmacol. 1976 Oct;26(5):599-605
    1. Eur J Pharmacol. 1977 Apr 7;42(3):285-90
    1. Naunyn Schmiedebergs Arch Pharmacol. 1977 Jan;296(2):91-7
    1. J Physiol. 1972 May;223(1):243-54
    1. J Physiol. 1973 Aug;233(1):195-209
    1. J Pharm Pharmacol. 1972 Jul;24(7):547-51
    1. J Pharmacol Exp Ther. 1969 Sep;169(1):17-22
    1. Eur J Pharmacol. 1972 Nov;20(2):171-80
    1. Arch Int Pharmacodyn Ther. 1974 Nov;212(1):89-102
    1. J Pharm Pharmacol. 1975 Aug;27(8):618-20
    1. Eur J Pharmacol. 1974 Jul;27(2):191-7
    1. Pol J Pharmacol Pharm. 1975 Jul-Aug;27(4):419-28
    1. Biochem Pharmacol. 1973 Nov 1;22(21):2753-9
    1. J Pharmacol Exp Ther. 1973 Sep;186(3):508-15
    1. J Pharmacol Exp Ther. 1973 May;185(2):328-35
    1. Biochem Pharmacol. 1972 Oct 1;21(19):2667-9
    1. J Neurochem. 1976 Feb;26(2):319-24
    1. Brain Res. 1976 Mar 5;104(1):107-19
    1. Boll Soc Ital Biol Sper. 1975 Nov 30;51(22):1716-22
    1. Pharmacol Biochem Behav. 1975 Jul-Aug;3(4):589-91
    1. Eur J Pharmacol. 1975 Feb;30(2):172-81
    1. J Pharmacol Exp Ther. 1970 Nov;175(2):427-34
    1. Eur J Pharmacol. 1970;10(3):339-43
    1. Biochem Pharmacol. 1969 Oct;18(10):2711-21
    1. Ann Med Exp Biol Fenn. 1969;47(2):113-23
    1. Science. 1968 Dec 13;162(3859):1290-2
    1. Psychopharmacologia. 1968;12(4):278-85

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner